Lipid Management in Renal Transplant Recipients Using Evolocumab.

PHASE4UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hyperlipidemias
Interventions
DRUG

Evolocumab

Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.

DRUG

Statins (Cardiovascular Agents)

Previously prescribed statin therapy.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT04608474 - Lipid Management in Renal Transplant Recipients Using Evolocumab. | Biotech Hunter | Biotech Hunter